Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
5806 | 1504 | 43.7 | 90% |
Classes in level above (level 2) |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | MK2 | Author keyword | 30 | 55% | 2% | 37 |
2 | MAPKAP K2 | Author keyword | 26 | 87% | 1% | 13 |
3 | MK5 | Author keyword | 23 | 100% | 1% | 10 |
4 | P38 ALPHA | Author keyword | 20 | 53% | 2% | 26 |
5 | PRAK | Author keyword | 18 | 89% | 1% | 8 |
6 | P38 GAMMA | Author keyword | 15 | 82% | 1% | 9 |
7 | P38 INHIBITORS | Author keyword | 15 | 77% | 1% | 10 |
8 | P38 ALPHA INHIBITORS | Author keyword | 14 | 100% | 0% | 7 |
9 | P38 MAP KINASE | Author keyword | 10 | 14% | 4% | 67 |
10 | P38 INHIBITOR | Author keyword | 8 | 62% | 1% | 8 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | MK2 | 30 | 55% | 2% | 37 | Search MK2 | Search MK2 |
2 | MAPKAP K2 | 26 | 87% | 1% | 13 | Search MAPKAP+K2 | Search MAPKAP+K2 |
3 | MK5 | 23 | 100% | 1% | 10 | Search MK5 | Search MK5 |
4 | P38 ALPHA | 20 | 53% | 2% | 26 | Search P38+ALPHA | Search P38+ALPHA |
5 | PRAK | 18 | 89% | 1% | 8 | Search PRAK | Search PRAK |
6 | P38 GAMMA | 15 | 82% | 1% | 9 | Search P38+GAMMA | Search P38+GAMMA |
7 | P38 INHIBITORS | 15 | 77% | 1% | 10 | Search P38+INHIBITORS | Search P38+INHIBITORS |
8 | P38 ALPHA INHIBITORS | 14 | 100% | 0% | 7 | Search P38+ALPHA+INHIBITORS | Search P38+ALPHA+INHIBITORS |
9 | P38 MAP KINASE | 10 | 14% | 4% | 67 | Search P38+MAP+KINASE | Search P38+MAP+KINASE |
10 | P38 INHIBITOR | 8 | 62% | 1% | 8 | Search P38+INHIBITOR | Search P38+INHIBITOR |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | ERK3 | 57 | 95% | 1% | 19 |
2 | P38 ALPHA | 35 | 45% | 4% | 58 |
3 | BENZOTHIOPHENE INHIBITORS | 34 | 93% | 1% | 13 |
4 | P38 MAP KINASE | 32 | 14% | 14% | 209 |
5 | CYTOKINE BIOSYNTHESIS | 31 | 56% | 3% | 38 |
6 | ACTIVATED PROTEIN KINASE 2 MK 2 | 29 | 88% | 1% | 14 |
7 | SB 203580 | 18 | 48% | 2% | 28 |
8 | CELLULAR STRESSES | 18 | 30% | 3% | 50 |
9 | MK5 | 18 | 83% | 1% | 10 |
10 | BIRB 796 | 17 | 100% | 1% | 8 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Mechanisms and functions of p38 MAPK signalling | 2010 | 293 | 165 | 42% |
Signal integration by JNK and p38 MAPK pathways in cancer development | 2009 | 635 | 159 | 31% |
p38 map kinases: Key signalling molecules as therapeutic targets for inflammatory diseases | 2003 | 682 | 66 | 68% |
Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease | 2015 | 2 | 33 | 52% |
Activation and signaling of the p38 MAP kinase pathway | 2005 | 551 | 114 | 38% |
New approaches to the treatment of inflammatory disorders small molecule inhibitors of p38 MAP kinase | 2006 | 95 | 74 | 84% |
P38 MAPK inhibitors: a patent review (2012-2013) | 2014 | 5 | 38 | 84% |
The many paths to p38 mitogen-activated protein kinase activation in the immune system | 2006 | 181 | 87 | 48% |
MAPKAP kinases - MKs - two's company, three's a crowd | 2006 | 221 | 111 | 41% |
P38 MAP-Kinases pathway regulation, function and role in human diseases | 2007 | 369 | 241 | 28% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | ANTIBIOT BIOARCHITECT GRP | 6 | 80% | 0.3% | 4 |
2 | SIGNAL DEPENDENT TRANSCRIPT | 4 | 50% | 0.4% | 6 |
3 | CANC OSTEOPOROSIS | 3 | 50% | 0.3% | 4 |
4 | SHOCK MICROCIRCULAT PLA | 3 | 42% | 0.3% | 5 |
5 | COMPUTAT STRUCT DRUG DISCOVERY | 2 | 67% | 0.1% | 2 |
6 | GRP MOL INFLAMMAT | 2 | 67% | 0.1% | 2 |
7 | MOL INFLAMMAT GRP | 2 | 43% | 0.2% | 3 |
8 | ZABLOCKI VET AFFAIRS MED | 2 | 22% | 0.4% | 6 |
9 | BIOL BIOMOL SCI | 1 | 31% | 0.3% | 4 |
10 | ALMIRALL S | 1 | 100% | 0.1% | 2 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000183402 | FR167653//ENDOTHELIUM INFLAMMATION//PHYSIOL EXPT PATHOL |
2 | 0.0000146613 | JNK//MKK4//JNK3 |
3 | 0.0000126936 | KSR1//PEA 15//IST ENDOCRINOL ONCOL SPERIMENTALE GAETANO SALVA |
4 | 0.0000097207 | BENZOYLOXY BENZOPHENONE//POST STUDIES BIOTECHNOL BIOINFO//YUVARAJA |
5 | 0.0000094232 | CARDIAC MED SECT//NHLI CARDIAC MED//BIOMED SCI MOL PATHOL |
6 | 0.0000083632 | ERK5//MEK5//EXTRACELLULAR SIGNAL REGULATED KINASE 5 ERK5 |
7 | 0.0000082076 | MKP 1//MAP KINASE PHOSPHATASE//DUAL SPECIFICITY PHOSPHATASE |
8 | 0.0000073394 | 2 4 5 TRISUBSTITUTED IMIDAZOLES//1 2 4 5 TETRASUBSTITUTED IMIDAZOLES//TETRASUBSTITUTED IMIDAZOLES |
9 | 0.0000072108 | TPL2//TPL 2//TPL2 KINASE |
10 | 0.0000070183 | COFFIN LOWRY SYNDROME//RSK2//SL0101 |